Interventional Cardiology Devices Market
Report Code
MD 3456
Published in
Feb, 2026, By MarketsandMarkets™
Interventional Cardiology Devices Market by Type (Angioplasty Stent, Catheter, Guidewire, Atherectomy, Drug Eluting/Cutting Balloon, IVUS/OCT, Vascular Closure Device, Plaque Modification Device, Hemodynamic Alteration Devices) - Global Forecast to 2031
$31.12B
MARKET SIZE, 2026
$42.39B
MARKET SIZE, 2031
6.4%
CAGR (2026-2031)
2026-2031
FORECAST PERIOD
INTERVENTIONAL CARDIOLOGY DEVICES MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global interventional cardiology devices market is projected to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a CAGR of 6.4% during the forecast period. The market was valued at USD 29.41 billion in 2025. Market growth is predominantly driven by the rising prevalence of cardiovascular diseases, including coronary artery disease and structural heart disorders, linked to population aging, sedentary lifestyles, and increasing rates of diabetes and obesity. The clinical shift from open-heart surgery toward minimally invasive, catheter-based interventions—offering shorter hospital stays, faster recovery, and lower complication rates—continues to accelerate device adoption, supported by next-generation drug-eluting stents, transcatheter heart valves, intravascular imaging (IVUS/OCT), and physiology-guided diagnostics.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 29.41 Billion
Current Market Size (2026): USD 31.12 Billion
Forecast Market Size (2031): USD 42.39 Billion
CAGR (2026–2031): 6.4% -
SEGMENT LEADERSHIP:
Angioplasty Stent Leader: Drug-eluting stents (DES) are expected to register the highest CAGR of 7.6% during the forecast period, driven by the persistent burden of coronary artery disease and a strong clinical preference for PCI over surgical revascularization.
Catheter Leader: IVUS/OCT catheters are expected to register the highest CAGR of 6.7% during the forecast period, while angiography catheters account for the largest market share.
Structural Heart Device Leader: Other therapy devices are estimated to dominate the structural heart devices market with a share of 57.3% in 2025.
End User Leader: Hospitals are estimated to dominate the market with a share of 83.1% in 2025, while ambulatory surgery centers represent the second-largest and fastest-growing end user. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Boston Scientific, Medtronic, and Abbott are among the major players in the interventional cardiology devices market. These companies offer comprehensive coronary, peripheral, and structural heart portfolios, emphasizing next-generation stents, intravascular imaging, and physiology-guided intervention.
Companies such as InSitu Technologies (US), Intravascular Imaging Incorporated (i3) (US), Agile Devices (US), and Evident Vascular (US) are among the emerging players in the market, distinguished by focused technical expertise and specialized device capabilities.
The rising global burden of cardiovascular disease and a strong shift toward minimally invasive, catheter-based care are prompting health systems to expand interventional cardiology programs. Manufacturers are emphasizing next-generation drug-eluting stents, bioresorbable scaffolds, intravascular imaging (IVUS/OCT), physiology-guided diagnostics, and AI-enabled cath-lab workflows. As selected procedures move toward ambulatory settings and catheterization-lab capacity expands in emerging markets, demand for precise, efficient, and cost-effective interventional devices is expected to rise steadily.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The figure highlights how the interventional cardiology devices market is converging across clinical, technological, and care-delivery dimensions. The strong movement toward transradial access—supported by faster recovery and lower cost—is guiding innovation in smaller-profile catheters, guidewires, stents, and vascular closure devices. Rapid adoption of intravascular imaging and physiology-guided assessment (IVUS, OCT, and pressure-based diagnostics) is improving procedural accuracy and expanding the range of complex PCI and structural heart interventions. The shift of selected procedures to ambulatory settings, the expansion of cath-lab capacity in emerging economies, and the transformation of cath labs into AI-enabled digital environments are major growth levers, even as value-based care and pricing pressures intensify competition.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Rising global burden of cardiovascular diseases
-
Technological advancements and innovations in interventional cardiology devices
RESTRAINTS
Impact
Level
Level
-
Risk of procedure-related complications
-
Product recalls and safety concerns
OPPORTUNITIES
Impact
Level
Level
-
High growth potential in emerging markets
-
Increasing adoption of structural heart therapies
CHALLENGES
Impact
Level
Level
-
Stringent regulatory requirements for product approvals
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising global burden of cardiovascular diseases
The market is driven significantly by the rising occurrence of cardiovascular diseases globally. Conditions such as coronary artery disease, peripheral artery disease, and structural heart disorders are increasingly prevalent among aging populations and those with obesity, diabetes, and hypertension. Cardiovascular disease is the leading cause of illness and death in many countries, producing a steady flow of diagnostic angiography and interventional procedures. Greater disease complexity and comorbidity are increasing the use of advanced catheter-based therapies suited to high-risk and elderly patients, supporting growth across hospitals and outpatient facilities.
Restraint: Risk of procedure-related complications
Even though there have been remarkable advances in interventional cardiology technology, procedural complications continue to be one of the major factors that can hinder some cardiac interventions from being widely adopted. Interventional cardiology procedures such as TAVR, PCI, atherectomy, and CTO interventions are accompanied by some risks, such as stroke, vascular problems, bleeding, arrhythmias, and repeat procedures.
Opportunity: High growth potential in emerging markets
The emerging markets, especially in the Asia Pacific, Latin America, and the Middle East regions, are likely to provide substantial growth opportunities for players in the interventional cardiology devices market. The factors fueling the adoption of cardiovascular interventions include rapid urbanization, improved healthcare infrastructure, high spending on healthcare, and a rise in cardiovascular diseases.
Challenge: Stringent regulatory requirements for product approvals
Strict regulatory requirements lengthen product development timelines and delay the introduction of new cardiac device technologies. Agencies such as the US FDA require costly preclinical studies, large clinical trials, and post-market surveillance, increasing development budgets and time to market for next-generation stents, drug-coated balloons, and advanced imaging catheters. Smaller and newer companies, with limited financial and clinical resources, are most affected—potentially reducing competition and innovation. Long, complex approval processes, high compliance costs, and unclear regulatory pathways continue to create barriers to entry.
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Through an extensive interventional cardiology portfolio, Boston Scientific supports coronary, peripheral, and structural heart procedures in the cath lab—spanning drug-eluting stents, angioplasty balloons, guidewires, atherectomy and intravascular lithotripsy, and structural heart solutions for complex cases, including high-risk PCI and left atrial appendage closure. | Devices support accurate procedures, lower restenosis rates, and treatment of difficult lesions, contributing to better long-term outcomes and quicker recovery | Strong clinical evidence, physician confidence, and compatibility with existing cath-lab infrastructure aid adoption in hospitals and ambulatory surgery centers. |
 |
Abbott offers coronary stents, intravascular imaging (IVUS/OCT), and physiologic assessment tools that guide PCI worldwide | Its integrated platforms help physicians assess lesion severity, optimize stent placement, and evaluate procedural results in real time across standard and complex coronary interventions. | Integration of imaging and physiology improves diagnostic accuracy and procedural decision-making, reducing unnecessary interventions and repeat procedures | This leads to better patient outcomes, greater procedural efficiency, and strong alignment with value-based care. |
 |
Medtronic's interventional cardiology products support coronary and peripheral interventions through advanced stents, drug-coated balloons, and catheter-based delivery systems, designed for both high-volume hospital cath labs and outpatient facilities across a wide range of disease severity. | A broad, well-supported portfolio and long-standing physician and hospital relationship enables reliable performance across diverse procedural settings, supporting efficient, minimally invasive treatment of cardiovascular disease. |
 |
Edwards focuses on structural heart therapy, particularly transcatheter heart valve replacement and repair, supported by extensive clinical evidence and continued innovation in delivery systems and valve design. | Minimally invasive structural heart solutions extend treatment to higher-risk and previously untreatable patients, improving outcomes and quality of life while reducing the need for open surgery. |
 |
Terumo provides a comprehensive coronary and vascular access portfolio—including guidewires, catheters, and transradial access solutions—supporting the global shift toward smaller-profile, radial-access interventions. | Radial-access and smaller-profile devices support faster recovery, lower bleeding risk, and reduced overall cost, enabling efficient minimally invasive procedures across hospitals and outpatient settings. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The interventional cardiology devices ecosystem consists of device manufacturers, component and raw-material suppliers, regulatory authorities, distributors, group purchasing organizations (GPOs), and end users such as hospitals, ambulatory surgical centers, cardiac care centers, and other end users such as catheterization labs and medical academic institutes. Manufacturers increasingly focus on next-generation stents and balloons, intravascular imaging, physiology-guided diagnostics, structural heart devices, and calcium-modification technologies, while regulatory bodies, reimbursement frameworks, and clinical evidence requirements shape product development and adoption.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Angioplasty Stents Market, by Type
Drug-eluting stents (DES) are the fastest-growing stent type and the standard of care in most PCI procedures, owing to their proven reduction of restenosis and repeat revascularization; ongoing innovation in struts, polymers, and bioresorbable materials is extending DES use into complex lesions.
Catheters Market, by Type
Angiography catheters hold the largest share on the strength of rising diagnostic and interventional procedure volumes, while IVUS/OCT catheters grow fastest as intravascular imaging becomes central to precise, evidence-based PCI.
Structural Heart Devices Market, by Type
Other therapy devices account for the largest share of the structural heart devices market, reflecting the expanding range of transcatheter interventions—such as left atrial appendage closure—beyond valve replacement, supported by accumulating clinical evidence.
Interventional Cardiology Devices Market, by End User
Hospitals account for the largest share due to high procedure volumes and established cath-lab infrastructure, while ambulatory surgery centers are the fastest-growing end user as selected low- to moderate-risk procedures shift to outpatient settings.
REGION
North America to be largest region in global interventional cardiology devices market during forecast period
North America dominates the interventional cardiology devices market because of a high cardiovascular disease burden, advanced catheterization-lab infrastructure, favorable reimbursement, rapid adoption of new technologies, and the presence of leading manufacturers with strong R&D pipelines. Rising volumes of complex coronary and structural heart interventions, along with the growing use of AI-powered imaging and navigation tools, further reinforce regional leadership.
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPANY EVALUATION MATRIX
In the interventional cardiology devices market matrix, Boston Scientific (Star) leads through a broad coronary, peripheral, and structural heart portfolio, deep cath-lab penetration, and strong clinical evidence, reinforced by acquisitions such as Bolt Medical in intravascular lithotripsy. Evident Vascular (Emerging Leader) is strengthening its position with next-generation intravascular imaging technology designed to improve procedural precision and address evolving clinical needs in complex PCI.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Boston Scientific Corporation (US)
- Medtronic (US)
- Abbott (US)
- Edwards Lifesciences Corporation (US)
- Terumo Corporation (Japan)
- B. Braun SE (Germany)
- Koninklijke Philips N.V. (Netherlands)
- Integer Holdings Corporation (US)
- Teleflex Incorporated (US)
- Asahi intecc co., ltd. (Japan)
- Cook (US)
- Cordis (US)
- iVascular S.L.U (Spain)
- Biosensors International Group, Ltd (Singapore)
- Endocor GmbH (Germany)
- InSitu Technologies Inc. (US)
- Cardionovum Gmbh (Germany)
- Medinol (Israel)
- Balton (UK)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 29.41 Billion |
| Market Forecast in 2026 (Value) | USD 31.12 Billion |
| Market Forecast in 2031 (Value) | USD 42.39 Billion |
| Growth Rate | CAGR of 6.4% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion), Volume (Thousand/Million Units) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Middle East & Africa, Latin America |
WHAT IS IN IT FOR YOU: INTERVENTIONAL CARDIOLOGY DEVICES MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Leading Medical Device Manufacturer (US) | Product Analysis: Comparison of interventional cardiology device types (stents, balloons, catheters, structural heart devices, plaque modification devices) across procedural precision, clinical evidence, indication coverage, and care-setting suitability. | Clear benchmarking of device strengths across outcomes, procedural efficiency, and indication breadth to support strategic portfolio and positioning decisions. |
| Leading Hospital Network (EU) | Company Information: Detailed profiling and evaluation of additional interventional cardiology device vendors (up to 5) across device types and end users, such as hospitals and ambulatory surgery centers. | Comprehensive assessment of product maturity, clinical specialization, and regional coverage to identify supply and partnership opportunities and support procurement and standardization strategies. |
RECENT DEVELOPMENTS
- May 2026 : Abbott received FDA clearance and a CE mark for Ultreon 3.0, an AI-enabled optical coherence tomography (OCT) intravascular imaging software platform. Using a one-second, infrared-light-based pullback with AI-automated insights, it delivers high-resolution coronary imaging with low or zero contrast and supports post-procedure stent assessment.
- April 2025 : Boston Scientific completed its acquisition of Bolt Medical, a developer of a laser-based intravascular lithotripsy (IVL) platform for calcified coronary and peripheral artery disease, following FDA 510(k) clearance of the Bolt IVL system for peripheral above-the-knee indications, strengthening its position in one of the fastest-growing interventional cardiology segments.
- February 2024 : Boston Scientific invested in expanding catheter and structural heart device manufacturing capacity at its domestic plants to support rising volumes of coronary interventions, transcatheter valve therapy, and complex peripheral procedures, while strengthening supply chain resilience.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
36
2
EXECUTIVE SUMMARY
41
3
PREMIUM INSIGHTS
47
4
MARKET OVERVIEW
Technological innovations and emerging markets drive transformative growth in interventional cardiology.
50
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
RISING GLOBAL BURDEN OF CARDIOVASCULAR DISEASES
4.2.1.2
TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN INTERVENTIONAL CARDIOLOGY DEVICES
4.2.1.3
INCREASING PREVALENCE OF DIABETES
4.2.1.4
GROWING ADOPTION OF MINIMALLY INVASIVE CARDIAC PROCEDURES
4.2.1.5
REIMBURSEMENT COVERAGE FOR INTERVENTIONAL CARDIOLOGY PROCEDURES
4.2.2
RESTRAINTS
4.2.2.1
RISK OF PROCEDURE-RELATED COMPLICATIONS
4.2.2.2
PRODUCT RECALLS AND SAFETY CONCERNS
4.2.3
OPPORTUNITIES
4.2.3.1
HIGH GROWTH POTENTIAL IN EMERGING MARKETS
4.2.3.2
INCREASING ADOPTION OF STRUCTURAL HEART THERAPIES
4.2.4
CHALLENGES
4.2.4.1
STRINGENT REGULATORY REQUIREMENTS FOR PRODUCT APPROVALS
4.3
UNMET NEEDS & WHITE SPACES
4.3.1
UNMET NEEDS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET
4.3.2
WHITE SPACE OPPORTUNITIES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1
INTERCONNECTED MARKETS
4.4.2
CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1
STRATEGIC MOVES IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET
5
INDUSTRY TRENDS
Navigate competitive pressures and capitalize on emerging trends in global medical device markets.
62
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC INDICATORS
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4
TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.4
VALUE CHAIN ANALYSIS
5.5
ECOSYSTEM ANALYSIS
5.5.1
MANUFACTURERS
5.5.2
END USERS
5.5.3
REGULATORY BODIES
5.6
PRICING ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2023–2025
5.6.2
AVERAGE SELLING PRICE TREND OF INTERVENTIONAL CARDIOLOGY DEVICES, BY REGION, 2023–2025
5.7
TRADE ANALYSIS
5.7.1
IMPORT DATA (HS CODE 9018)
5.7.2
EXPORT DATA FOR (HS CODE 9018)
5.7.3
IMPORT DATA (HS CODE 9021)
5.7.4
EXPORT DATA FOR (HS CODE 9021)
5.8
REIMBURSEMENT SCENARIO
5.9
KEY CONFERENCES & EVENTS, 2026–2027
5.10
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.11
INVESTMENT & FUNDING SCENARIO
5.12
CASE STUDY ANALYSIS
5.13
IMPACT OF 2025 US TARIFFS ON INTERVENTIONAL CARDIOLOGY DEVICES MARKET
5.13.1
INTRODUCTION
5.13.2
KEY TARIFF RATES
5.13.3
PRICE IMPACT ANALYSIS
5.13.4
IMPACT ON COUNTRY/REGION
5.13.5
IMPACT ON END-USE SEGMENTS
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations redefine interventional cardiology with personalized, data-driven procedures and advanced imaging technologies.
91
6.1
TECHNOLOGY ANALYSIS
6.1.1
KEY EMERGING TECHNOLOGIES
6.1.1.1
ADVANCED IMAGING & AI-ASSISTED GUIDANCE SYSTEMS
6.1.1.2
ROBOTICS & PRECISION NAVIGATION TECHNOLOGIES
6.1.2
COMPLEMENTARY TECHNOLOGIES
6.1.2.1
ADVANCED INTRAVASCULAR IMAGING MODALITIES
6.1.2.2
INTRAVASCULAR IMAGING (IVUS/OCT)
6.1.3
ADJACENT TECHNOLOGIES
6.1.3.1
WEARABLES & REMOTE MONITORING INTEGRATED WITH INTERVENTIONAL CARE
6.2
TECHNOLOGY/PRODUCT ROADMAP
6.2.1
NEAR TERM (2025–2027)
6.2.2
MID TERM (2028–2030)
6.2.3
LONG TERM (2030+)
6.3
PATENT ANALYSIS
6.3.1
JURISDICTION & TOP APPLICANT ANALYSIS
6.4
FUTURE APPLICATIONS
6.4.1
AI-ENABLED & DATA-DRIVEN PROCEDURE OPTIMIZATION
6.4.2
PERSONALIZED CARDIOVASCULAR INTERVENTIONS
6.4.3
CONNECTED CARDIOVASCULAR WORKFLOWS & DIGITAL INTEGRATION
6.5
IMPACT OF AI/GEN AI ON INTERVENTIONAL CARDIOLOGY DEVICES
6.5.1
INTRODUCTION
6.5.2
MARKET POTENTIAL OF AI IN INTERVENTIONAL CARDIOLOGY DEVICES
6.5.3
AI USE CASES
6.5.4
KEY COMPANIES IMPLEMENTING AI
7
SUSTAINABILITY & REGULATORY LANDSCAPE
Navigate global regulations and sustainability strategies to optimize eco-friendly medical device practices.
102
7.1
REGULATORY LANDSCAPE
7.1.1
REGULATORY FRAMEWORK
7.1.1.1
NORTH AMERICA
7.1.1.2
EUROPE
7.1.1.3
ASIA PACIFIC
7.1.1.4
LATIN AMERICA
7.1.1.5
MIDDLE EAST & AFRICA
7.1.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.3
INDUSTRY STANDARDS
7.2
SUSTAINABILITY INITIATIVES
7.2.1
REDUCING SINGLE-USE MEDICAL DEVICE WASTE
7.2.2
USE OF LOWER-IMPACT MATERIALS AND PACKAGING
7.2.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock growth by addressing unmet needs and decision-making barriers in interventional cardiology markets.
109
8.1
KEY STAKEHOLDERS & BUYING CRITERIA
8.1.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.1.2
BUYING CRITERIA
8.2
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2.1
DECISION-MAKING PROCESS
8.2.2
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.2.3
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2.4
MARKET PROFITABILITY
9
ANGIOPLASTY STENTS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 12 Data Tables
115
9.1
INTRODUCTION
9.1.1
DRUG-ELUTING STENTS
9.1.1.1
SUPERIOR CLINICAL OUTCOMES AND ONGOING PRODUCT INNOVATIONS TO SUPPORT MARKET GROWTH
9.1.1.2
GLOBAL VOLUME ANALYSIS OF DRUG-ELUTING STENTS, 2024–2031 (THOUSAND UNITS)
9.1.2
BARE-METAL STENTS
9.1.2.1
COST ADVANTAGES AND CONTINUED ADOPTION IN RESOURCE-CONSTRAINED HEALTHCARE SETTINGS TO SUPPORT DEMAND
9.1.2.2
GLOBAL VOLUME ANALYSIS OF BARE-METAL STENTS, 2024–2031 (THOUSAND UNITS)
9.1.3
BIOABSORBABLE STENTS
9.1.3.1
ADVANCEMENTS IN RESORBABLE SCAFFOLD TECHNOLOGIES TO BOOST SEGMENTAL GROWTH
9.1.3.2
GLOBAL VOLUME ANALYSIS OF BIOABSORBABLE STENTS, 2024–2031 (THOUSAND UNITS)
10
STRUCTURAL HEART DEVICES MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 8 Data Tables
125
10.1
INTRODUCTION
10.1.1
AORTIC VALVE THERAPY DEVICES
10.1.1.1
RISING BURDEN OF AORTIC STENOSIS AND EXPANDING ADOPTION OF TAVI PROCEDURES TO FUEL GROWTH
10.1.1.2
GLOBAL VOLUME ANALYSIS OF AORTIC VALVE THERAPY DEVICES, 2024–2031 (THOUSAND UNITS)
10.1.2
OTHER THERAPY DEVICES
10.1.2.1
GLOBAL VOLUME ANALYSIS OF OTHER THERAPY DEVICES, 2024–2031 (THOUSAND UNITS)
11
CATHETERS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 11 Data Tables
133
11.1
INTRODUCTION
11.1.1
ANGIOGRAPHY CATHETERS
11.1.1.1
GROWING CARDIOVASCULAR DISEASE BURDEN AND ADVANCEMENTS IN CATHETER TECHNOLOGIES TO SUPPORT MARKET GROWTH
11.1.1.2
GLOBAL VOLUME ANALYSIS OF ANGIOGRAPHY CATHETERS MARKET, 2024–2031 (THOUSAND UNITS)
11.1.2
GUIDING CATHETERS
11.1.2.1
GROWING ADOPTION OF COMPLEX CORONARY INTERVENTIONS TO DRIVE MARKET GROWTH
11.1.2.2
GLOBAL VOLUME ANALYSIS OF GUIDING CATHETERS MARKET, 2024–2031 (THOUSAND UNITS)
11.1.3
IVUS/OCT CATHETERS
11.1.3.1
INCREASING ADOPTION OF INTRAVASCULAR IMAGING TECHNOLOGIES TO DRIVE DEMAND
11.1.3.2
GLOBAL VOLUME ANALYSIS OF IVUS/OCT CATHETERS MARKET, 2024–2031 (THOUSAND UNITS)
12
ANGIOPLASTY BALLOONS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 11 Data Tables
143
12.1
INTRODUCTION
12.1.1
OLD/NORMAL BALLOONS
12.1.1.1
LOW TREATMENT COSTS ASSOCIATED WITH OLD/NORMAL BALLOONS TO DRIVE GROWTH
12.1.1.2
GLOBAL VOLUME ANALYSIS OF OLD/NORMAL BALLOONS MARKET, 2024–2031 (THOUSAND UNITS)
12.1.2
DRUG-ELUTING BALLOONS
12.1.2.1
INCREASING REGULATORY APPROVALS AND EXPANDING CLINICAL ADOPTION TO CONTRIBUTE TO MARKET GROWTH
12.1.2.2
GLOBAL VOLUME ANALYSIS OF DRUG ELUTING BALLOONS MARKET, 2024–2031 (THOUSAND UNITS)
12.1.3
CUTTING/SCORING BALLOONS
12.1.3.1
INCREASING USE IN COMPLEX AND CALCIFIED LESION TREATMENT TO SUPPORT SEGMENTAL GROWTH
12.1.3.2
GLOBAL VOLUME ANALYSIS OF CUTTING/SCORING BALLOONS MARKET, 2024–2031 (THOUSAND UNITS)
13
PLAQUE MODIFICATION DEVICES MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 8 Data Tables
153
13.1
INTRODUCTION
13.1.1
THROMBECTOMY DEVICES
13.1.1.1
ABILITY TO REMOVE BLOOD CLOTS IN STEMI AND NSTEMI PATIENTS TO PROPEL MARKET
13.1.1.2
GLOBAL VOLUME ANALYSIS OF THROMBECTOMY DEVICES MARKET, 2024–2031 (THOUSAND UNITS)
13.1.2
ATHERECTOMY DEVICES
13.1.2.1
GROWING BURDEN OF CALCIFIED CORONARY LESIONS TO DRIVE MARKET GROWTH
13.1.2.2
GLOBAL VOLUME ANALYSIS OF ATHERECTOMY DEVICES MARKET, 2024–2031 (THOUSAND UNITS)
14
HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 8 Data Tables
161
14.1
INTRODUCTION
14.1.1
EMBOLIC PROTECTION DEVICES
14.1.1.1
EXPANDING USE OF HIGH-RISK CARDIOVASCULAR INTERVENTIONS TO PROPEL MARKET GROWTH
14.1.1.2
GLOBAL VOLUME ANALYSIS OF EMBOLIC PROTECTION DEVICES MARKET, 2024–2031 (THOUSAND UNITS)
14.1.2
CHRONIC TOTAL OCCLUSION DEVICES
14.1.2.1
RISING COMPLEXITY OF CORONARY LESIONS TO FUEL MARKET GROWTH
14.1.2.2
GLOBAL VOLUME ANALYSIS OF CHRONIC TOTAL OCCLUSION DEVICES MARKET, 2024–2031 (THOUSAND UNITS)
15
OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 17 Data Tables
169
15.1
INTRODUCTION
15.1.1
GUIDEWIRES
15.1.1.1
INCREASING ADOPTION IN COMPLEX CORONARY INTERVENTIONS TO SUPPORT MARKET GROWTH
15.1.1.2
GLOBAL VOLUME ANALYSIS OF GUIDEWIRES MARKET, 2024–2031 (THOUSAND UNITS)
15.1.2
VASCULAR CLOSURE DEVICES
15.1.2.1
INCREASING FOCUS ON FASTER HEMOSTASIS AND REDUCED ACCESS-SITE COMPLICATIONS TO AID MARKET GROWTH
15.1.2.2
GLOBAL VOLUME ANALYSIS OF VASCULAR CLOSURE DEVICES MARKET, 2024–2031 (THOUSAND UNITS)
15.1.3
INTRODUCER SHEATHS
15.1.3.1
INCREASING DEMAND FOR SAFE AND RELIABLE VASCULAR ACCESS TO SUPPORT MARKET GROWTH
15.1.3.2
GLOBAL VOLUME ANALYSIS OF INTRODUCER SHEATHS MARKET, 2024–2031 (THOUSAND UNITS)
15.1.4
BALLOON INFLATION DEVICES
15.1.4.1
RISING ADOPTION OF BALLOON-BASED INTERVENTIONS IN MINIMALLY INVASIVE PROCEDURES TO BOOST MARKET GROWTH
15.1.4.2
GLOBAL VOLUME ANALYSIS OF BALLOON INFLATION DEVICES MARKET, 2024–2031 (THOUSAND UNITS)
15.1.5
HEMOSTASIS HEART VALVES
15.1.5.1
INCREASING FOCUS ON PROCEDURAL PRECISION AND CONTROLLED HEMOSTASIS TO SUPPORT MARKET GROWTH
15.1.5.2
GLOBAL VOLUME ANALYSIS OF HEMOSTASIS HEART VALVES MARKET, 2024–2031 (THOUSAND UNITS)
16
INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 8 Data Tables
184
16.1
INTRODUCTION
16.2
HOSPITALS
16.2.1
AVAILABILITY OF ADVANCED INFRASTRUCTURE AND SPECIALIZED EQUIPMENT TO DRIVE MARKET
16.3
AMBULATORY SURGERY CENTERS
16.3.1
SHIFT TOWARD COST-EFFICIENT AND OUTPATIENT-BASED CARE MODELS TO SUPPORT MARKET GROWTH
16.4
CARDIAC CARE CENTERS
16.4.1
GROWING IMPORTANCE OF CARDIAC CARE CENTERS IN DELIVERING SPECIALIZED CARDIOVASCULAR INTERVENTIONS TO FUEL GROWTH
16.5
OTHER END USERS
17
INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 18 Countries | 298 Data Tables.
194
17.1
INTRODUCTION
17.2
NORTH AMERICA
17.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
17.2.2
NORTH AMERICA: VOLUME ANALYSIS OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2024–2031 (THOUSAND UNITS)
17.2.3
US
17.2.3.1
FAVORABLE REIMBURSEMENT COVERAGE AND GROWING CARDIOVASCULAR DISEASE BURDEN TO SUPPORT MARKET GROWTH
17.2.4
CANADA
17.2.4.1
RISING CARDIOVASCULAR DISEASE BURDEN AND ADVANCEMENTS IN CARDIAC CARE TO DRIVE MARKET GROWTH
17.3
EUROPE
17.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
17.3.2
EUROPE: VOLUME ANALYSIS OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2024–2031 (THOUSAND UNITS)
17.3.3
GERMANY
17.3.3.1
KEY HUB FOR ADVANCED INTERVENTIONAL CARDIOLOGY TECHNOLOGIES TO BOOST MARKET
17.3.4
FRANCE
17.3.4.1
GOVERNMENT SUPPORT FOR CARDIOVASCULAR CARE AND TECHNOLOGICAL INNOVATION TO DRIVE MARKET GROWTH IN FRANCE
17.3.5
UK
17.3.5.1
INCREASING ADOPTION OF ADVANCED AND PERSONALIZED CARDIOVASCULAR THERAPIES TO SUPPORT MARKET GROWTH
17.3.6
ITALY
17.3.6.1
RISING PREVALENCE OF CARDIOVASCULAR RISK FACTORS TO DRIVE DEMAND FOR INTERVENTIONAL CARDIOLOGY DEVICES
17.3.7
SPAIN
17.3.7.1
AGING POPULATION AND INCREASING CARDIOVASCULAR DISEASE BURDEN TO SUPPORT MARKET GROWTH
17.3.8
REST OF EUROPE
17.4
ASIA PACIFIC
17.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
17.4.2
ASIA PACIFIC: VOLUME ANALYSIS OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2024–2031 (THOUSAND UNITS)
17.4.3
CHINA
17.4.3.1
HIGH TOBACCO CONSUMPTION AND RISING CARDIOVASCULAR DISEASE BURDEN DRIVING MARKET GROWTH
17.4.4
JAPAN
17.4.4.1
AGING POPULATION AND GROWING DEMAND FOR MINIMALLY INVASIVE CARDIAC PROCEDURES TO DRIVE MARKET GROWTH
17.4.5
INDIA
17.4.5.1
RISING CARDIOVASCULAR DISEASE BURDEN AND EXPANDING HEALTHCARE ACCESS TO DRIVE MARKET GROWTH
17.4.6
AUSTRALIA
17.4.6.1
RISING PREVALENCE OF LIFESTYLE-RELATED CARDIOVASCULAR DISEASES TO DRIVE MARKET GROWTH
17.4.7
SOUTH KOREA
17.4.7.1
ADVANCEMENTS IN MEDICAL TECHNOLOGY AND CARDIOVASCULAR CARE TO SUPPORT MARKET GROWTH
17.4.8
REST OF ASIA PACIFIC
17.5
LATIN AMERICA
17.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
17.5.2
LATIN AMERICA: VOLUME ANALYSIS OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2024–2031 (THOUSAND UNITS)
17.5.3
BRAZIL
17.5.3.1
RISING CARDIOVASCULAR DISEASE BURDEN AND HEALTHCARE INFRASTRUCTURE INVESTMENTS TO DRIVE MARKET GROWTH
17.5.4
MEXICO
17.5.4.1
RISING DIABETES AND CARDIOVASCULAR DISEASE BURDEN TO DRIVE MARKET GROWTH
17.5.5
REST OF LATIN AMERICA
17.6
MIDDLE EAST & AFRICA
17.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
17.6.2
MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF INTERVENTIONAL CARDIOLOGY DEVICES, BY TYPE, 2024–2031 (THOUSAND UNITS)
17.6.3
GCC COUNTRIES
17.6.3.1
RISING DIABETES AND CARDIOVASCULAR DISEASE BURDEN TO DRIVE MARKET GROWTH
17.6.4
KINGDOM OF SAUDI ARABIA (KSA)
17.6.4.1
EXPANDING CARDIOVASCULAR CARE INFRASTRUCTURE AND HEALTHCARE INVESTMENTS TO SUPPORT MARKET GROWTH IN SAUDI ARABIA
17.6.5
UNITED ARAB EMIRATES (UAE)
17.6.5.1
HEALTHCARE MODERNIZATION AND ADVANCED CARDIOVASCULAR CARE TO SUPPORT MARKET GROWTH IN THE UAE
17.6.6
OTHER GCC COUNTRIES
17.6.7
REST OF MIDDLE EAST & AFRICA
18
COMPETITIVE LANDSCAPE
Discover market dominance strategies shaping interventional cardiology's competitive landscape through 2025.
317
18.1
OVERVIEW
18.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
18.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET
18.3
REVENUE ANALYSIS, 2023–2025
18.4
MARKET SHARE ANALYSIS, 2025
18.4.1
ANGIOPLASTY STENTS MARKET SHARE ANALYSIS, 2025
18.4.2
STRUCTURAL HEART DEVICES MARKET SHARE ANALYSIS, 2025
18.4.3
CATHETERS MARKET SHARE ANALYSIS, 2025
18.4.4
ANGIOPLASTY BALLOONS MARKET SHARE ANALYSIS, 2025
18.4.5
PLAQUE MODIFICATION DEVICES MARKET SHARE ANALYSIS, 2025
18.4.6
HEMODYNAMIC FLOW ALTERATION DEVICES MARKET SHARE ANALYSIS, 2025
18.4.7
OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET SHARE ANALYSIS, 2025
18.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
18.5.1
STARS
18.5.2
EMERGING LEADERS
18.5.3
PERVASIVE PLAYERS
18.5.4
PARTICIPANTS
18.6
COMPANY FOOTPRINT
18.6.1
COMPANY FOOTPRINT: KEY PLAYERS, 2025
18.6.1.1
COMPANY FOOTPRINT
18.6.1.2
REGION FOOTPRINT
18.6.1.3
PRODUCT FOOTPRINT
18.6.1.4
ANGIOPLASTY STENTS FOOTPRINT
18.6.1.5
STRUCTURAL HEART DEVICES FOOTPRINT
18.6.1.6
CATHETERS FOOTPRINT
18.6.1.7
ANGIOPLASTY BALLOONS FOOTPRINT
18.6.1.8
PLAQUE MODIFICATION DEVICES FOOTPRINT
18.6.1.9
HEMODYNAMIC FLOW ALTERATION DEVICES FOOTPRINT
18.6.1.10
OTHER INTERVENTIONAL CARDIOLOGY DEVICES FOOTPRINT
18.6.1.11
END-USER FOOTPRINT
18.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
18.7.1
PROGRESSIVE COMPANIES
18.7.2
RESPONSIVE COMPANIES
18.7.3
DYNAMIC COMPANIES
18.7.4
STARTING BLOCKS
18.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
18.8
COMPANY VALUATION & FINANCIAL METRICS
18.8.1
FINANCIAL METRICS
18.8.2
COMPANY VALUATION
18.9
BRAND/PRODUCT COMPARATIVE ANALYSIS
18.10
COMPETITIVE SCENARIO
18.10.1
PRODUCT LAUNCHES & APPROVALS
18.10.2
DEALS
18.10.3
EXPANSIONS
19
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
352
19.1
KEY PLAYERS
19.1.1
EDWARDS LIFESCIENCES CORPORATION
19.1.1.1
BUSINESS OVERVIEW
19.1.1.2
PRODUCTS OFFERED
19.1.1.3
RECENT DEVELOPMENTS
19.1.1.3.1
PRODUCT LAUNCHES & APPROVALS
19.1.1.3.2
DEALS
19.1.1.4
MNM VIEW
19.1.1.4.1
KEY STRENGTHS
19.1.1.4.2
STRATEGIC CHOICES
19.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
19.1.2
ABBOTT
19.1.3
MEDTRONIC
19.1.4
BOSTON SCIENTIFIC CORPORATION
19.1.5
TERUMO CORPORATION
19.1.6
KONINKLIJKE PHILIPS N.V.
19.1.7
CORDIS
19.1.8
TELEFLEX INCORPORATED
19.1.9
ASAHI INTECC CO., LTD.
19.1.10
COOK
19.1.11
B. BRAUN SE
19.1.12
INTEGER HOLDINGS CORPORATION
19.1.13
LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.
19.1.14
IVASCULAR S.L.U.
19.1.15
BIOSENSORS INTERNATIONAL GROUP, LTD.
19.2
OTHER PLAYERS
19.2.1
ENDOCOR GMBH & CO. KG
19.2.2
INSITU TECHNOLOGIES, INC.
19.2.3
MERIL LIFE SCIENCES PVT. LTD
19.2.4
ALVIMEDICA
19.2.5
CARDIONOVUM GMBH
19.2.6
MEDINOL
19.2.7
BALTON SP.
19.2.8
TRANSLUMINA
19.2.9
SINO MEDICAL SCIENCES TECHNOLOGY INC.
19.2.10
SMT
20
RESEARCH METHODOLOGY
439
20.1
RESEARCH DATA
20.1.1
SECONDARY DATA
20.1.1.1
KEY SECONDARY SOURCES
20.1.2
PRIMARY DATA
20.1.2.1
PRIMARY SOURCES
20.1.2.2
KEY DATA FROM PRIMARY SOURCES
20.1.2.3
KEY INDUSTRY INSIGHTS
20.1.2.4
BREAKDOWN OF PRIMARIES
20.2
MARKET SIZE ESTIMATION
20.2.1
APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH
20.2.2
APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
20.2.3
APPROACH 3: TOP-DOWN APPROACH
20.2.4
APPROACH 4: BOTTOM-UP APPROACH
20.2.5
APPROACH 4: PRIMARY INTERVIEWS
20.2.6
APPROACH 5: DEMAND-SIDE APPROACH
20.2.7
APPROACH 6: VOLUME DATA ANALYSIS
20.3
DATA TRIANGULATION AND MARKET BREAKDOWN
20.4
MARKET SHARE ASSESSMENT
20.5
RESEARCH ASSUMPTIONS
20.5.1
STUDY ASSUMPTIONS
20.5.2
GROWTH RATE ASSUMPTIONS
20.6
RISK ASSESSMENT
20.6.1
RESEARCH LIMITATIONS
21
APPENDIX
458
21.1
DISCUSSION GUIDE
21.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3
CUSTOMIZATION OPTIONS
21.4
RELATED REPORTS
21.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
INCLUSIONS & EXCLUSIONS
TABLE 2
STANDARD CURRENCY CONVERSION RATES (UNIT OF USD)
TABLE 3
DIABETES POPULATION, BY REGION, 2024 VS. 2050
TABLE 4
FDA MEDICAL DEVICE USER FEE STRUCTURE (MDUFA VI – FY2025)
TABLE 5
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 6
GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION)
TABLE 7
LIST OF KEY INTERVENTIONAL CARDIOLOGY DEVICE MANUFACTURERS
TABLE 8
LIST OF KEY END USERS
TABLE 9
LIST OF KEY REGULATORY BODIES
TABLE 10
AVERAGE SELLING PRICE TREND OF ANGIOPLASTY STENTS, BY TYPE, 2023–2025 (USD)
TABLE 11
AVERAGE SELLING PRICE OF DRUG-ELUTING STENTS, BY KEY PLAYER, 2025 (USD)
TABLE 12
AVERAGE SELLING PRICE TREND OF CATHETERS, BY TYPE, 2023–2025 (USD)
TABLE 13
AVERAGE SELLING PRICE TREND OF INTERVENTIONAL CARDIOLOGY DEVICES, BY REGION, 2023–2025 (USD)
TABLE 14
IMPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 15
EXPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 16
IMPORT DATA FOR HS CODE 9021-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 17
EXPORT DATA FOR HS CODE 9021-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 18
KEY BILLING CODES USED FOR INTERVENTIONAL CARDIOLOGY DEVICE CATEGORIES
TABLE 19
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027
TABLE 20
EDWARDS SAPIEN 3 ULTRA RESILIA VALVE: SEVERE AORTIC STENOSIS PATIENT
TABLE 21
ABBOTT MITRACLIP: SEVERE RHEUMATIC MITRAL REGURGITATION
TABLE 22
BOSTON SCIENTIFIC WATCHMAN FLX: STROKE PREVENTION IN HIGH BLEEDING-RISK AF PATIENT
TABLE 23
RECIPROCAL TARIFF RATES ADJUSTED BY US, 2025
TABLE 24
KEY PRODUCT-RELATED TARIFF
TABLE 25
NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA
TABLE 26
ASIA PACIFIC: IMPACT OF US TARIFFS ON CHINA, JAPAN, AND INDIA
TABLE 27
EUROPE: IMPACT OF US TARIFFS ON GERMANY AND UK
TABLE 28
LATIN AMERICA: IMPACT OF US TARIFFS ON MEXICO
TABLE 29
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: KEY PATENTS, 2023–2025
TABLE 30
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 31
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 32
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 33
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 34
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 35
INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INTERVENTIONAL CARDIOLOGY DEVICES
TABLE 36
KEY BUYING CRITERIA FOR INTERVENTIONAL CARDIOLOGY DEVICES, BY END USER
TABLE 37
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 38
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
TABLE 39
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: KEY PROFITABILITY DRIVERS
TABLE 40
INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 41
ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 42
ANGIOPLASTY STENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43
KEY PLAYERS PROVIDING DRUG-ELUTING STENTS
TABLE 44
DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45
DRUG-ELUTING STENTS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 46
KEY PLAYERS PROVIDING BARE-METAL STENTS
TABLE 47
BARE-METAL STENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48
BARE METAL STENTS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 49
KEY PLAYERS PROVIDING BIOABSORBABLE STENTS
TABLE 50
BIOABSORBABLE STENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51
BIOABSORBABLE STENTS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 52
STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 53
STRUCTURAL HEART DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54
KEY PLAYERS PROVIDING AORTIC VALVE THERAPY DEVICES
TABLE 55
AORTIC VALVE THERAPY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
AORTIC VALVE THERAPY DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 57
KEY PLAYERS PROVIDING OTHER THERAPY DEVICES
TABLE 58
OTHER THERAPY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59
OTHER THERAPY DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 60
CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 61
CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62
KEY PLAYERS PROVIDING ANGIOGRAPHY CATHETERS
TABLE 63
ANGIOGRAPHY CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64
ANGIOGRAPHY CATHETERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 65
KEY PLAYERS PROVIDING GUIDING CATHETERS
TABLE 66
GUIDING CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67
GUIDING CATHETERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 68
KEY PLAYERS PROVIDING IVUS/OCT CATHETERS
TABLE 69
IVUS/OCT CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70
IVUS/OCT CATHETERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 71
ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 72
ANGIOPLASTY BALLOONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73
KEY PLAYERS PROVIDING OLD/NORMAL BALLOONS
TABLE 74
OLD/NORMAL ANGIOPLASTY BALLOONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75
OLD/NORMAL BALLOONS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 76
KEY PLAYERS PROVIDING DRUG-ELUTING BALLOONS
TABLE 77
DRUG-ELUTING BALLOONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78
DRUG-ELUTING BALLOONS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 79
KEY PLAYERS PROVIDING CUTTING/SCORING BALLOONS
TABLE 80
CUTTING/SCORING BALLOONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81
CUTTING/SCORING BALLOONS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 82
PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 83
PLAQUE MODIFICATION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84
KEY PLAYERS PROVIDING THROMBECTOMY DEVICES
TABLE 85
THROMBECTOMY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86
THROMBECTOMY DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 87
KEY PLAYERS PROVIDING ATHERECTOMY DEVICES
TABLE 88
ATHERECTOMY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89
ATHERECTOMY DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 90
HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 91
HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92
KEY PLAYERS PROVIDING EMBOLIC PROTECTION DEVICES
TABLE 93
EMBOLIC PROTECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94
EMBOLIC PROTECTION DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 95
KEY PLAYERS PROVIDING CHRONIC TOTAL OCCLUSION DEVICES
TABLE 96
CHRONIC TOTAL OCCLUSION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97
CHRONIC TOTAL OCCLUSION DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 98
OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 99
OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100
KEY PLAYERS PROVIDING GUIDEWIRES
TABLE 101
GUIDEWIRES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102
GUIDEWIRES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 103
KEY PLAYERS PROVIDING VASCULAR CLOSURE DEVICES
TABLE 104
VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105
VASCULAR CLOSURE DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 106
KEY PLAYERS PROVIDING INTRODUCER SHEATHS
TABLE 107
INTRODUCER SHEATHS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108
INTRODUCER SHEATHS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 109
KEY PLAYERS PROVIDING BALLOON INFLATION DEVICES
TABLE 110
BALLOON INFLATION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111
BALLOON INFLATION DEVICES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 112
KEY PLAYERS PROVIDING HEMOSTASIS HEART VALVES
TABLE 113
HEMOSTASIS HEART VALVES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114
HEMOSTASIS HEART VALVES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 115
INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 116
INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117
INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 118
INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR STANDALONE HOSPITAL FACILITIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119
INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR LARGE CHAIN HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120
INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121
INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR CARDIAC CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122
INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123
INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 124
NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 125
NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126
NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 127
NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128
NORTH AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 129
NORTH AMERICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 130
NORTH AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 131
NORTH AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 132
NORTH AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 133
NORTH AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 134
NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 135
NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 136
US: MACROECONOMIC INDICATORS
TABLE 137
US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 138
US: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 139
US: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 140
US: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141
US: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 142
US: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 143
US: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 144
US: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 145
US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 146
US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 147
CANADA: MACROECONOMIC INDICATORS
TABLE 148
CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 149
CANADA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 150
CANADA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151
CANADA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152
CANADA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 153
CANADA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 154
CANADA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 155
CANADA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 156
CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 157
CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 158
EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 159
EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160
EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 161
EUROPE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162
EUROPE: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 163
EUROPE: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 164
EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 165
EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 166
EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167
EUROPE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168
EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 169
EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 170
GERMANY: MACROECONOMIC INDICATORS
TABLE 171
GERMANY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 172
GERMANY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 173
GERMANY: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 174
GERMANY: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 175
GERMANY: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 176
GERMANY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177
GERMANY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178
GERMANY: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179
GERMANY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 180
GERMANY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 181
FRANCE: MACROECONOMIC INDICATORS
TABLE 182
FRANCE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 183
FRANCE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 184
FRANCE: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 185
FRANCE: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 186
FRANCE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 187
FRANCE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 188
FRANCE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189
FRANCE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 190
FRANCE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 191
FRANCE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 192
UK: MACROECONOMIC INDICATORS
TABLE 193
UK: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 194
UK: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195
UK: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196
UK: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 197
UK: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 198
UK: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199
UK: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 200
UK: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 201
UK: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 202
UK: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 203
ITALY: MACROECONOMIC INDICATORS
TABLE 204
ITALY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 205
ITALY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206
ITALY: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 207
ITALY: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208
ITALY: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 209
ITALY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 210
ITALY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 211
ITALY: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212
ITALY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 213
ITALY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 214
SPAIN: MACROECONOMIC INDICATORS
TABLE 215
SPAIN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 216
SPAIN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 217
SPAIN: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 218
SPAIN: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 219
SPAIN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 220
SPAIN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 221
SPAIN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222
SPAIN: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 223
SPAIN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 224
SPAIN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 225
REST OF EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 226
REST OF EUROPE; ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227
REST OF EUROPE: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 228
REST OF EUROPE: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 229
REST OF EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 230
REST OF EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231
REST OF EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 232
REST OF EUROPE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 233
REST OF EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 234
REST OF EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 235
ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 236
ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237
ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 238
ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239
ASIA PACIFIC: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 240
ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 241
ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 242
ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 243
ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 244
ASIA PACIFIC: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 245
ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 246
ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 247
CHINA: MACROECONOMIC INDICATORS
TABLE 248
CHINA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 249
CHINA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 250
CHINA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 251
CHINA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 252
CHINA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253
CHINA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 254
CHINA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 255
CHINA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 256
CHINA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 257
CHINA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258
JAPAN: MACROECONOMIC INDICATORS
TABLE 259
JAPAN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 260
JAPAN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 261
JAPAN: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 262
JAPAN CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 263
JAPAN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 264
JAPAN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 265
JAPAN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 266
JAPAN: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 267
JAPAN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 268
JAPAN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269
INDIA: MACROECONOMIC INDICATORS
TABLE 270
INDIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 271
INDIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 272
INDIA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 273
INDIA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 274
INDIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 275
INDIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 276
INDIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 277
INDIA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 278
INDIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 279
INDIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 280
AUSTRALIA: MACROECONOMIC INDICATORS
TABLE 281
AUSTRALIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 282
AUSTRALIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 283
AUSTRALIA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 284
AUSTRALIA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 285
AUSTRALIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 286
AUSTRALIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 287
AUSTRALIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288
AUSTRALIA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 289
AUSTRALIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 290
AUSTRALIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 291
SOUTH KOREA: MACROECONOMIC INDICATORS
TABLE 292
SOUTH KOREA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 293
SOUTH KOREA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 294
SOUTH KOREA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 295
SOUTH KOREA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 296
SOUTH KOREA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297
SOUTH KOREA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298
SOUTH KOREA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 299
SOUTH KOREA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 300
SOUTH KOREA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 301
SOUTH KOREA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302
REST OF ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 303
REST OF ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 304
REST OF ASIA PACIFIC: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 305
REST OF ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 306
REST OF ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 307
REST OF ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 308
REST OF ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 309
REST OF ASIA PACIFIC: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 310
REST OF ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 311
REST OF ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 312
LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 313
LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 314
LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 315
LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 316
LATIN AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 317
LATIN AMERICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 318
LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 319
LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 320
LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 321
LATIN AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 322
LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 323
LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 324
BRAZIL: MACROECONOMIC INDICATORS
TABLE 325
BRAZIL: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 326
BRAZIL: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 327
BRAZIL: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 328
BRAZIL: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 329
BRAZIL: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 330
BRAZIL: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 331
BRAZIL: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 332
BRAZIL: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 333
BRAZIL: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 334
BRAZIL: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 335
MEXICO: MACROECONOMIC INDICATORS
TABLE 336
MEXICO: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 337
MEXICO: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 338
MEXICO: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 339
MEXICO: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 340
MEXICO: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 341
MEXICO: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 342
MEXICO: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 343
MEXICO: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 344
MEXICO: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 345
MEXICO: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 346
REST OF LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 347
REST OF LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 348
REST OF LATIN AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 349
REST OF LATIN AMERICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 350
REST OF LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 351
REST OF LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 352
REST OF LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 353
REST OF LATIN AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 354
REST OF LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 355
REST OF LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 356
MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 357
MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 358
MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 359
MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 360
MIDDLE EAST & AFRICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 361
MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 362
MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 363
MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 364
MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 365
MIDDLE EAST & AFRICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 366
MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 367
MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 368
GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 369
GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 370
GCC COUNTRIES: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 371
GCC COUNTRIES: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 372
GCC COUNTRIES: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 373
GCC COUNTRIES: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 374
GCC COUNTRIES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 375
GCC COUNTRIES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 376
GCC COUNTRIES: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 377
GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 378
GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 379
KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
TABLE 380
KINGDOM OF SAUDI ARABIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 381
KINGDOM OF SAUDI ARABIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 382
KINGDOM OF SAUDI ARABIA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 383
KINGDOM OF SAUDI ARABIA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 384
KINGDOM OF SAUDI ARABIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 385
KINGDOM OF SAUDI ARABIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 386
KINGDOM OF SAUDI ARABIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 387
KINGDOM OF SAUDI ARABIA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 388
KINGDOM OF SAUDI ARABIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 389
KINGDOM OF SAUDI ARABIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 390
UNITED ARAB EMIRATES: KEY MACROINDICATORS
TABLE 391
UNITED ARAB EMIRATES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 392
UNITED ARAB EMIRATES: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 393
UNITED ARAB EMIRATES: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 394
UNITED ARAB EMIRATES: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 395
UNITED ARAB EMIRATES: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 396
UNITED ARAB EMIRATES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 397
UNITED ARAB EMIRATES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 398
UNITED ARAB EMIRATES: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 399
UNITED ARAB EMIRATES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 400
UNITED ARAB EMIRATES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 401
OTHER GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 402
OTHER GCC COUNTRIES: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 403
OTHER GCC COUNTRIES: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 404
OTHER GCC COUNTRIES: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 405
OTHER GCC COUNTRIES: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 406
OTHER GCC COUNTRIES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 407
OTHER GCC COUNTRIES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 408
OTHER GCC COUNTRIES: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 409
OTHER GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 410
OTHER GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 411
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 412
REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 413
REST OF MIDDLE EAST & AFRICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 414
REST OF MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 415
REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 416
REST OF MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 417
REST OF MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 418
REST OF MIDDLE EAST & AFRICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 419
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 420
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY HOSPITALS, 2024–2031 (USD MILLION)
TABLE 421
OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES, JANUARY 2023–MAY 2026
TABLE 422
ANGIOPLASTY STENTS MARKET: DEGREE OF COMPETITION
TABLE 423
STRUCTURAL HEART DEVICES MARKET: DEGREE OF COMPETITION
TABLE 424
CATHETERS MARKET: DEGREE OF COMPETITION
TABLE 425
ANGIOPLASTY BALLOONS MARKET: DEGREE OF COMPETITION
TABLE 426
PLAQUE MODIFICATION DEVICES MARKET: DEGREE OF COMPETITION
TABLE 427
HEMODYNAMIC FLOW ALTERATION DEVICES MARKET: DEGREE OF COMPETITION
TABLE 428
OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DEGREE OF COMPETITION
TABLE 429
REGION FOOTPRINT
TABLE 430
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PRODUCT FOOTPRINT
TABLE 431
ANGIOPLASTY STENTS FOOTPRINT
TABLE 432
STRUCTURAL HEART DEVICES FOOTPRINT
TABLE 433
CATHETERS FOOTPRINT
TABLE 434
ANGIOPLASTY BALLOONS FOOTPRINT
TABLE 435
PLAQUE MODIFICATION DEVICES FOOTPRINT
TABLE 436
HEMODYNAMIC FLOW ALTERATION DEVICES FOOTPRINT
TABLE 437
OTHER INTERVENTIONAL CARDIOLOGY DEVICES FOOTPRINT
TABLE 438
END-USER FOOTPRINT
TABLE 439
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 440
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 441
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 442
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DEALS, JANUARY 2023– MAY 2026
TABLE 443
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 444
EDWARDS LIFESCIENCES CORPORATION: COMPANY OVERVIEW
TABLE 445
EDWARDS LIFESCIENCES CORPORATION: PRODUCTS OFFERED
TABLE 446
EDWARDS LIFESCIENCES CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 447
EDWARDS LIFESCIENCES CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 448
ABBOTT: COMPANY OVERVIEW
TABLE 449
ABBOTT: PRODUCTS OFFERED
TABLE 450
ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 451
ABBOTT: DEALS, JANUARY 2023–MAY 2026
TABLE 452
MEDTRONIC: COMPANY OVERVIEW
TABLE 453
MEDTRONIC: PRODUCTS OFFERED
TABLE 454
MEDTRONIC: PRODUCT APPROVALS, JANUARY 2023–MAY 2026
TABLE 455
MEDTRONIC: DEALS, JANUARY 2023–MAY 2026
TABLE 456
BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
TABLE 457
BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
TABLE 458
BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 459
BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 460
TERUMO CORPORATION: COMPANY OVERVIEW
TABLE 461
TERUMO CORPORATION: PRODUCTS OFFERED
TABLE 462
TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026
TABLE 463
TERUMO CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 464
TERUMO CORPORATION.: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 465
TERUMO CORPORATION.: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 466
KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
TABLE 467
KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
TABLE 468
KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 469
KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2023–MAY 2026
TABLE 470
CORDIS: COMPANY OVERVIEW
TABLE 471
CORDIS.: PRODUCTS OFFERED
TABLE 472
CORDIS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 473
CORDIS: DEALS, JANUARY 2023–MAY 2026
TABLE 474
TELEFLEX INCORPORATED: COMPANY OVERVIEW
TABLE 475
TELEFLEX INCORPORATED: PRODUCTS OFFERED
TABLE 476
TELEFLEX INCORPORATED: PRODUCT APPROVALS, JANUARY 2023–MAY 2026
TABLE 477
TELEFLEX INCORPORATED.: DEALS, JANUARY 2023–MAY 2026
TABLE 478
ASAHI INTECC CO., LTD.: COMPANY OVERVIEW
TABLE 479
ASAHI INTECC CO., LTD.: PRODUCTS OFFERED
TABLE 480
ASAHI INTECC CO., LTD.: DEALS, JANUARY 2023–MAY 2026
TABLE 481
ASAHI INTECC CO., LTD: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 482
COOK: COMPANY OVERVIEW
TABLE 483
COOK: PRODUCTS OFFERED
TABLE 484
COOK: DEALS, JANUARY 2023–MAY 2026
TABLE 485
B. BRAUN SE: COMPANY OVERVIEW
TABLE 486
B. BRAUN SE: PRODUCTS OFFERED
TABLE 487
B. BRAUN SE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 488
B. BRAUN SE: DEALS, JANUARY 2023–MAY 2026
TABLE 489
INTEGER HOLDINGS CORPORATION: COMPANY OVERVIEW
TABLE 490
INTEGER HOLDINGS CORPORATION: PRODUCTS OFFERED
TABLE 491
INTEGER HOLDINGS CORPORATION.: DEALS, JANUARY 2023–MAY 2026
TABLE 492
INTEGER HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 493
LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: COMPANY OVERVIEW
TABLE 494
LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD: PRODUCTS OFFERED
TABLE 495
IVASCULAR S.L.U.: COMPANY OVERVIEW
TABLE 496
IVASCULAR S.L.U: PRODUCTS OFFERED
TABLE 497
BIOSENSORS INTERNATIONAL GROUP, LTD.: COMPANY OVERVIEW
TABLE 498
BIOSENSORS INTERNATIONAL GROUP, LTD.: PRODUCTS OFFERED
TABLE 499
STUDY ASSUMPTIONS
TABLE 500
RISK ASSESSMENT ANALYSIS
LIST OF FIGURES
FIGURE 1
INTERVENTIONAL CARDIOLOGY DEVICES MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 1
MARKET SCENARIO
FIGURE 2
GLOBAL INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2024–2031
FIGURE 3
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2023–2025
FIGURE 4
DISRUPTIONS INFLUENCING GROWTH OF INTERVENTIONAL CARDIOLOGY DEVICES MARKET
FIGURE 5
HIGH-GROWTH SEGMENTS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2026–2031
FIGURE 6
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 7
STRONG FUTURE FOR MINIMALLY INVASIVE AND ADVANCED CARDIOVASCULAR INTERVENTIONS TO BOOST MARKET GROWTH
FIGURE 8
HOSPITALS AND CHINA DOMINATED MARKET IN 2025
FIGURE 9
CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 10
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 12
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 13
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: VALUE CHAIN ANALYSIS
FIGURE 14
INTERVENTIONAL CARDIOLOGY DEVICES MARKET ECOSYSTEM
FIGURE 15
AVERAGE SELLING PRICE TREND OF STRUCTURAL HEART DEVICES, BY TYPE, 2023–2025 (USD)
FIGURE 16
AVERAGE SELLING PRICE OF ANGIOPLASTY STENTS, BY REGION, 2025 (USD)
FIGURE 17
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 18
INVESTMENT & FUNDING SCENARIO
FIGURE 19
TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR INTERVENTIONAL CARDIOLOGY DEVICE PATENTS, JANUARY 2015–MAY 2026
FIGURE 20
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: AI USE CASES
FIGURE 21
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INTERVENTIONAL CARDIOLOGY DEVICES
FIGURE 22
KEY BUYING CRITERIA FOR INTERVENTIONAL CARDIOLOGY DEVICES, BY END USER
FIGURE 23
NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET SNAPSHOT
FIGURE 24
ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET SNAPSHOT
FIGURE 25
REVENUE ANALYSIS OF KEY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2023−2025)
FIGURE 26
ANGIOPLASTY STENTS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27
STRUCTURAL HEART DEVICES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 28
CATHETERS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29
ANGIOPLASTY BALLOONS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 30
PLAQUE MODIFICATION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 31
HEMODYNAMIC FLOW ALTERATION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 32
OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 33
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 34
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPANY FOOTPRINT
FIGURE 35
INTERVENTIONAL CARDIOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 36
EV/EBITDA OF KEY VENDORS
FIGURE 37
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 38
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 39
EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 40
ABBOTT: COMPANY SNAPSHOT (2025)
FIGURE 41
MEDTRONIC: COMPANY SNAPSHOT (2025)
FIGURE 42
BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 43
TERUMO CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 44
KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2025)
FIGURE 45
TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2025)
FIGURE 46
ASAHI INTECC CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 47
B. BRAUN SE: COMPANY SNAPSHOT (2025)
FIGURE 48
INTEGER HOLDINGS CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 49
LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 50
INTERVENTIONAL CARDIOLOGY DEVICES MARKET: RESEARCH DESIGN
FIGURE 51
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 52
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 53
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
FIGURE 54
RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 55
MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS
FIGURE 56
REVENUE SHARE ANALYSIS ILLUSTRATION: MEDTRONIC (2025)
FIGURE 57
TOP-DOWN APPROACH
FIGURE 58
BOTTOM-UP APPROACH
FIGURE 59
DEMAND-SIDE APPROACH
FIGURE 60
CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2026–2031)
FIGURE 61
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 62
DATA TRIANGULATION METHODOLOGY
Methodology
Secondary research was conducted to gather information for this technical, market-oriented, and commercial study of the global interventional cardiology devices market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain through primary research. Different approaches, such as top-down and bottom-up, were used to estimate the total market size. After that, market breakup and data triangulation procedures were used to estimate the sizes of the market segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources were consulted to identify and collect information for the study. These sources included annual reports, press releases, and investor presentations from device manufacturers; regulatory filings and clearance databases; clinical literature and peer-reviewed journals; cardiology society guidelines and registries; certified publications; and white papers. Secondary research was primarily used to obtain key information on the industry's supply chain, the total pool of key players, market classification and segmentation according to industry trends down to the most granular level, regional markets, and key developments from both market- and technology-oriented perspectives. All of this information was further validated by primary sources.
Primary Research
In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Supply-side sources included industry experts such as Chief Executive Officers (CEOs), Vice Presidents (VPs), product and R&D directors, regulatory affairs leaders, and other key executives from companies operating in the market. Demand-side participants included interventional cardiologists, catheterization lab directors and staff, hospital procurement and supply chain leaders, and group purchasing organization (GPO) representatives.
In the market engineering process, top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to estimate and forecast the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was conducted throughout the market engineering process to present key information and insights throughout the report.
After the complete market engineering process—including calculations for market statistics, market breakups, market size estimates, market forecasts, and data triangulation—extensive primary research was conducted to gather information and verify and validate the critical numbers derived. Primary research was also used to identify segmentation types, industry trends, the competitive landscape, and key market dynamics, including drivers, restraints, opportunities, challenges, and key strategies.
Note 1: Others include cath-lab managers, procurement managers, biomedical engineers, and clinical consultants.
Note 2: Tier 1 companies have revenues higher than USD 10 billion; Tier 2 companies have revenues between USD 1 and 10 billion; and Tier 3 companies have revenues between USD 500 million and USD 1 billion.
Note 3: The breakup above represents an indicative list of primary profiles.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Top-down and bottom-up approaches were used to estimate and validate the size of the interventional cardiology devices market and the sizes of its dependent subsegments. The research methodology used to estimate market size included identifying key market players through secondary research and determining their market shares in each region through both primary and secondary research. This entire procedure included the study of the annual and financial reports of the top market players, and extensive interviews were conducted with key industry leaders, such as CEOs, VPs, directors, and marketing executives, to gain key insights.
All percentage splits and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the market covered in this research study have been accounted for, examined in extensive detail, verified through primary research, and analyzed to obtain the final quantitative and qualitative data. This data is consolidated and combined with detailed inputs and analysis from MarketsandMarkets.
Data Triangulation
After determining the overall market size using the market size estimation processes explained above, the market was segmented into several segments and subsegments. Data triangulation and market breakup procedures were employed, where applicable, to complete the overall market engineering process and derive the exact statistics for each market segment and subsegment. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.
Market Definition
Interventional cardiology devices are minimally invasive, catheter-based medical devices used to diagnose and treat cardiovascular conditions, including coronary artery disease, peripheral artery disease, and structural heart disorders. The category includes angioplasty stents (drug-eluting and bare-metal), angioplasty balloons, catheters (angiography, guiding, and IVUS/OCT), structural heart devices, plaque-modification devices, hemodynamic flow-alteration devices, and other devices such as guidewires and introducer sheaths. These devices enable percutaneous coronary intervention (PCI), transcatheter structural heart therapy, and image- and physiology-guided diagnosis, supporting safer, less invasive treatment across hospital and ambulatory care settings.
Key Stakeholders
- Interventional cardiology device manufacturers and suppliers
- Hospitals, catheterization laboratories, and ambulatory surgery centers
- Interventional cardiologists, cardiac surgeons, and cath-lab staff
- Hospital procurement teams and group purchasing organizations (GPOs)
- Healthcare payers and reimbursement authorities
- Distributors, dealers, and contract manufacturers
- Regulatory authorities and cardiology standards organizations
- Research institutes and academic medical centers
- Investors and technology partners
Report Objectives
- To describe and forecast the global interventional cardiology devices market by type, end user, and region from 2026 to 2031, and to analyze the various macroeconomic and microeconomic factors that affect market growth
- To forecast the market size of five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
- To analyze the subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
- To provide detailed information regarding the major factors (drivers, restraints, opportunities, and challenges) influencing market growth
- To analyze opportunities in the market for stakeholders and to provide details of the competitive landscape of major players
- To profile key market players and comprehensively analyze their business overviews, regional presence, product offerings, business strategies, and key financials, and to illustrate the competitive landscape of the market
- To analyze competitive developments such as mergers & acquisitions, product launches, partnerships & collaborations, and research & development (R&D) activities in the market
Available customizations:
With the provided market data, MarketsandMarkets offers customizations tailored to company-specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakup of the Asia Pacific market into countries contributing to the rest of the regional market size.
- Further breakup of the North American market into countries contributing to the rest of the regional market size.
- Further breakup of the European market into countries contributing to the rest of the regional market size.
- Further breakup of the Latin American market into countries contributing to the rest of the regional market size.
- Further breakup of the Middle East & African market into countries contributing to the rest of the regional market size.
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Interventional Cardiology Devices Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in Interventional Cardiology Devices Market
Siri
May, 2022
what are the growth opportunities in interventional cardiovascular devices market.
Benjamin
Mar, 2022
Looking forward to gain more insights on the global Interventional Cardiology Devices Market.
Samuel
Mar, 2022
Can you enlighten us on geographical growth analysis in Interventional Cardiology Devices Market?.